摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Ethylphenyl)-4,4-difluorobutane-1,3-dione | 832741-19-2

中文名称
——
中文别名
——
英文名称
1-(4-Ethylphenyl)-4,4-difluorobutane-1,3-dione
英文别名
——
1-(4-Ethylphenyl)-4,4-difluorobutane-1,3-dione化学式
CAS
832741-19-2
化学式
C12H12F2O2
mdl
——
分子量
226.223
InChiKey
NZKGGXZCRXAKHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2914700090

SDS

SDS:40c869f4d0b22b85328ee3769f4727fa
查看

反应信息

  • 作为反应物:
    描述:
    4-amino-3,5-dichloro-6-hydrazinylpyridine-2-carbonitrile 、 1-(4-Ethylphenyl)-4,4-difluorobutane-1,3-dione硫酸 作用下, 以 乙醇 为溶剂, 反应 4.0h, 生成 4-amino-3,5-dichloro-6-(3-(difluoromethyl)-5-(4-ethylphenyl)-1H-pyrazol-1-yl)picolinic acid
    参考文献:
    名称:
    新型 6-(5-芳基取代-1-吡唑基)-2-吡啶甲酸作为潜在除草剂的设计、合成、除草活性和构效关系研究。
    摘要:
    吡啶甲酸和吡啶甲酸盐化合物是一类卓越的合成植物生长素除草剂。近年来,两种新的吡啶甲酸酯类化合物甲基卤昔芬(ArylexTM 活性)和氟吡唑醚苄基(RinskorTM 活性)已作为新型除草剂上市。以其结构骨架为模板,设计合成了33个4-amino-3,5-dicholor-6-(5-aryl-substituted-1-pytazolyl)-2-picolinic acid化合物,用于发现具有强效除草作用的化合物活动。测试化合物对拟南芥根部生长的抑制活性,结果表明化合物V-7的IC50值比商业除草剂halauxifen-methyl低45倍。分子对接分析表明,化合物 V-7 与受体生长素信号转导 F-box 蛋白 5 (AFB5) 的对接比毒草胺更密集。根据这些 IC50 值构建自适应三维定量构效关系模型,以指导下一步的合成策略。新化合物的除草试验表明,化合物V-8在300 gha-1剂量下
    DOI:
    10.3390/molecules28031431
  • 作为产物:
    描述:
    二氟乙酸乙酯对乙基苯乙酮 在 sodium hydride 作用下, 以 乙醚 为溶剂, 生成 1-(4-Ethylphenyl)-4,4-difluorobutane-1,3-dione
    参考文献:
    名称:
    新型 6-(5-芳基取代-1-吡唑基)-2-吡啶甲酸作为潜在除草剂的设计、合成、除草活性和构效关系研究。
    摘要:
    吡啶甲酸和吡啶甲酸盐化合物是一类卓越的合成植物生长素除草剂。近年来,两种新的吡啶甲酸酯类化合物甲基卤昔芬(ArylexTM 活性)和氟吡唑醚苄基(RinskorTM 活性)已作为新型除草剂上市。以其结构骨架为模板,设计合成了33个4-amino-3,5-dicholor-6-(5-aryl-substituted-1-pytazolyl)-2-picolinic acid化合物,用于发现具有强效除草作用的化合物活动。测试化合物对拟南芥根部生长的抑制活性,结果表明化合物V-7的IC50值比商业除草剂halauxifen-methyl低45倍。分子对接分析表明,化合物 V-7 与受体生长素信号转导 F-box 蛋白 5 (AFB5) 的对接比毒草胺更密集。根据这些 IC50 值构建自适应三维定量构效关系模型,以指导下一步的合成策略。新化合物的除草试验表明,化合物V-8在300 gha-1剂量下
    DOI:
    10.3390/molecules28031431
点击查看最新优质反应信息

文献信息

  • [EN] TETRAHYDROPYRAZOLO [1,5 -A] PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS<br/>[FR] COMPOSÉS ANTITUBERCULEUX À BASE DE TÉTRAHYDRO-PYRAZOLO[1,5 -A]PYRIMIDINE
    申请人:GLAXO GROUP LTD
    公开号:WO2012143522A1
    公开(公告)日:2012-10-26
    A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 represents a group selected from: i) phenyl optionally substituted with one or two substituents independently selected from Me, OMe, CF3, F, CI and NMe2; ii) furanyl, thiophenyl, pyrrolyl, pyridyl, cyclohexyl or naphthyl, each of which is optionally substituted with one or two substituents independently selected from Me, OMe, CF3, F, CI and NMe2; and iii) benzo[1,3]dioxo5-yl or 2,3-dihydrobenzo[1,4]dioxin-6-yl; R2 represents CF3, C1-4alkyl, or CHF2; When R1 represents optionally substituted furanyl, thiophenyl, pyrrolyl, pyridyl or naphthyl, R3 represents Et; When R1 represents optionally substituted cyclohexyl, R3 represents Et or Me; Otherwise R3 represents Et, Me, Br or OMe, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided, together with certain novel compounds
    化合物的化学式(I)或其药用盐,其中R1代表以下之一的基团:i)苯基,可选择一个或两个取代基,独立选择自Me、OMe、CF3、F、CI和NMe2;ii)呋喃基、噻吩基、吡咯基、吡啶基、环己基或基,每个基团可选择一个或两个取代基,独立选择自Me、OMe、 、F、CI和NMe2;iii)苯并[1,3]二氧杂环戊烯-5-基或2,3-二氢苯并[1,4]二氧杂环戊烷-6-基;R2代表 、C1-4烷基或CHF2;当R1代表可选择的取代基呋喃基、噻吩基、吡咯基、吡啶基或基时,R3代表乙基;当R1代表可选择的取代基环己基时,R3代表乙基或甲基;否则R3代表乙基、甲基、或OMe,含有它们的组合物,它们在治疗中的用途,例如在结核病治疗中的用途,以及制备这类化合物的方法,以及一些新颖的化合物。
  • TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS
    申请人:Alvarez-Ruiz Emilio
    公开号:US20140038989A1
    公开(公告)日:2014-02-06
    A compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein: R 1 represents a group selected from: i) phenyl optionally substituted with one or two substituents independently selected from Me, OMe, CF 3 , F, Cl and NMe 2 ; furanyl, thiophenyl, pyrrolyl, pyridyl, cyclohexyl or naphthyl, each of which is optionally substituted with one or two substituents independently selected from Me, OMe, CF 3 , F, Cl and NMe 2 ; and iii) benzo[1,3]dioxo5-yl or 2,3-dihydrobenzo[1,4]dioxin-6-yl; R 2 represents CF 3 , C 1-4 alkyl, or CHF 2 ; when R 1 represents optionally substituted furanyl, thiophenyl, pyrrolyl, pyridyl or naphthyl, R 3 represents Et; when R 1 represents optionally substituted cyclohexyl, R 3 represents Et or Me; otherwise R 3 represents Et, Me, Br or OMe, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided, together with certain novel compounds.
    提供化合物公式(I)或其药学上可接受的盐:其中:R1代表从以下选择的基团:i)苯基,可选地用一个或两个取代基独立地选自Me,OMe,CF3,F,Cl和NMe2;呋喃基,噻吩基,吡咯基,吡啶基,环己基或基,每个基团可选地用一个或两个取代基独立地选自Me,OMe, ,F,Cl和NMe2;和iii)苯并[1,3]二氧杂环戊-5-基或2,3-二氢苯并[1,4]二氧杂环己-6-基;R2代表 ,C1-4烷基或CHF2;当R1代表可选取代的呋喃基,噻吩基,吡咯基,吡啶基或基时,R3代表Et;当R1代表可选取代的环己基时,R3代表Et或Me;否则,R3代表Et,Me,Br或OMe,提供包含它们的组合物,它们在治疗中的用途,例如在结核病的治疗中,并提供制备这些化合物的方法,以及某些新化合物。
  • Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine
    作者:Jin Li、Kristin M.Lundy DeMello、Henry Cheng、Subas M. Sakya、Brian S. Bronk、Robert J. Rafka、Burton H. Jaynes、Carl B. Ziegler、Carolyn Kilroy、Donald W. Mann、Eric L. Nimz、Michael P. Lynch、Michelle L. Haven、Nicole L. Kolosko、Martha L. Minich、Chao Li、Jason K. Dutra、Bryson Rast、Rhonda M. Crosson、Barry J. Morton、Glen W. Kirk、Kathleen M. Callaghan、David A. Koss、Andrei Shavnya、Lisa A. Lund、Scott B. Seibel、Carol F. Petras、Annette Silvia
    DOI:10.1016/j.bmcl.2003.10.004
    日期:2004.1
    Structure-activity relationship (SAR) studies of 2-[3-di(and tri)fluoromethyl-5-arylpyrazol-1-yl]-5-methanesulfonylpyridine derivatives for canine COX enzymes are described. This led to the identification of 12a as a lead candidate for further progression. The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted. (C) 2003 Elsevier Ltd. All rights reserved.
  • Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore
    作者:Sunil K. Singh、V. Saibaba、K. Srinivasa Rao、P. Ganapati Reddy、Pankaj R. Daga、S. Abdul Rajjak、Parimal Misra、Y. Koteswar Rao
    DOI:10.1016/j.ejmech.2005.03.016
    日期:2005.10
    Diverse analogs of 1,5-diarylpyrazoles having 3-hydroxymethyl-4-sulfamoyl (SO2NH2)/methyl sulfonyl (SO2Me)-pheny group at N-1 were synthesized and evaluated for their in vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The SAR study mainly involved the variations at positions C-3, C-5 and N-1 of the pyrazole ring. Several small hydrophobic groups at/around position-4 of C-5 phenyl, viz. 3,4-dimethylphenyl analog 9, 3-methyl-4-methylsulfanylphenyl analog 14 and 2,3-dihydrobenzo[b]thiophenyl analog 17, exhibited impressive COX-2 inhibitory potency. In general, the sulfonamide analogues with a CHF2 at C-3 were found to be more potent than those having a CF3 group. The three dimensional quantitative structure activity relationship comprising comparative molecular field analysis (3D-QSAR-CoMFA) afforded the models with high predictivity which further validated the acceptance of hydroxymethyl (CH2OH) group in the hydrophilic pocket of the COX-2 enzyme. (c) 2005 Elsevier SAS. All rights reserved.
  • TETRAHYDROPYRAZOLO [1,5 -A]PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS
    申请人:Glaxo Group Limited
    公开号:EP2699577A1
    公开(公告)日:2014-02-26
查看更多